Fixed monthly versus less frequent ranibizumab dosing and predictors of visual response in exudative age-related macular degeneration

Journal of Ophthalmology

Volumn 2012, Issue , 2012, Pages

  Hariprasad, Seenu M ^a   Morse, Lawrence S ^b   Shapiro, Howard ^c   Wong, Pamela ^c   Tuomi, Lisa ^c  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873867315     PISSN: 2090004X     EISSN: 20900058     Source Type: Journal    
DOI: 10.1155/2012/690641     Document Type: Article

References (13)

1. Brown D. M., Kaiser P. K., Michels M., Soubrane G., Heier J. S., Kim R. Y., Sy J. P., Schneider S., Ranibizumab versus verteporfin for neovascular age-related macular degeneration. New England Journal of Medicine 2006 355 14 1432 1444 2-s2.0-33749451356 10.1056/NEJMoa062655 (Pubitemid 44511558)
2. Rosenfeld P. J., Brown D. M., Heier J. S., Boyer D. S., Kaiser P. K., Chung C. Y., Kim R. Y., Ranibizumab for neovascular age-related macular degeneration. New England Journal of Medicine 2006 355 14 1419 1431 2-s2.0-33749445317 10.1056/NEJMoa054481 (Pubitemid 44511557)
3. Regillo C. D., Brown D. M., Abraham P., Yue H., Ianchulev T., Schneider S., Shams N., Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. American Journal of Ophthalmology 2008 145 2 239.e5 248.e5 2-s2.0-38349172455 10.1016/j.ajo.2007.10.004
4. Boyer D. S., Heier J. S., Brown D. M., Francom S. F., Ianchulev T., Rubio R. G., A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009 116 9 1731 1739 2-s2.0-69249222585 10.1016/j.ophtha.2009.05.024
5. Fung A. E., Lalwani G. A., Rosenfeld P. J., Dubovy S. R., Michels S., Feuer W. J., Puliafito C. A., Davis J. L., Flynn H. W., Esquiabro M., An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. American Journal of Ophthalmology 2007 143 4 566.e2 583.e2 2-s2.0-33947403618 10.1016/j.ajo.2007.01.028 (Pubitemid 46452533)
6. Lalwani G. A., Rosenfeld P. J., Fung A. E., Dubovy S. R., Michels S., Feuer W., Davis J. L., Flynn H. W., Esquiabro M., A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. American Journal of Ophthalmology 2009 148 1 43.e1 58.e1 2-s2.0-67149101784 10.1016/j.ajo.2009.01.024
7. Spaide R., Ranibizumab according to need: a treatment for age-related macular degeneration. American Journal of Ophthalmology 2007 143 4 679 680 2-s2.0-33947361190 10.1016/j.ajo.2007.02.024 (Pubitemid 46452536)
8. Martin D. F., Maguire M. G., Ying G. S., Grunwald J. E., Fine S. L., Jaffe G. J., Ranibizumab and bevacizumab for neovascular age-related macular degeneration. New England Journal of Medicine 2011 364 20 1897 1908 2-s2.0-79956218863 10.1056/NEJMoa1102673
9. Ikemori S., Kato A., Yasukawa T., Effect of a single-dose regimen of intravitreal ranibizumab in the treatment of neovascular age-related macular degeneration. Journal of Clinical and Experimental Ophthalmology 2012 3 221
10. Carneiro A. M., Mendonça L. S., Falcão M. S., Fonseca S. L., Brandão E. M., Falcão-Reis F. M., Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting. Clinical Ophthalmology 2012 6 1 1149 1157 2-s2.0-84861332315 http://dx.doi.org/10.2147/OPTH.S33017
11. Gupta O. P., Shienbaum G., Patel A. H., Fecarotta C., Kaiser R. S., Regillo C. D., A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration: clinical and economic impact. Ophthalmology 2010 117 11 2134 2140 2-s2.0-78049279239 10.1016/j.ophtha.2010.02.032
12. Boyer D. S., Antoszyk A. N., Awh C. C., Bhisitkul R. B., Shapiro H., Acharya N. R., Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007 114 2 246 252 2-s2.0-33846586501 10.1016/j.ophtha.2006.10.045 (Pubitemid 46172497)
13. Kaiser P. K., Brown D. M., Zhang K., Hudson H. L., Holz F. G., Shapiro H., Schneider S., Acharya N. R., Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. American Journal of Ophthalmology 2007 144 6 850.e4 857.e4 2-s2.0-36249002808 10.1016/j.ajo.2007.08.012 (Pubitemid 350130239)